Anti-aging supplement maker ROKIT America files for a $35 million IPO
May 8, 2026 News
Anti-aging supplement maker ROKIT America sets terms for $25 million IPO
ROKIT America, which is anti-aging supplement provider spun out of South Korea’s ROKIT Healthcare, announced terms for its IPO on Friday.
The Los Angeles, CA-based company plans to raise $25 million by offering 2.6 million shares at a price range of $8.50 to $10.50.
IPO Overview
ROKIT America, which is anti-aging supplement provider spun out of South Korea’s ROKIT Healthcare, filed on Wednesday with the SEC to raise up to $35 million in an initial public offering.
The company develops and sells dietary supplements focused on cellular health and aging-related wellness, primarily centered on β-Nicotinamide Mononucleotide （NMN） formulations. Its flagship products combine NMN with additional ingredients such as pterostilbene and fisetin, and are marketed in the US and other global markets as consumer wellness supplements. In addition to its supplement business, the company is developing an AI-enabled organ regeneration platform through technology from its parent, ROKIT Healthcare, aimed at future regenerative medicine applications in the Americas. The company’s products are regulated as dietary supplements and do not require premarket approval by the FDA.
The Los Angeles, CA-based company was founded in 2012 and booked $7 million in revenue for the 12 months ended December 31, 2025. It plans to list on the Nasdaq under the symbol RKAM. ROKIT America filed confidentially on October 2, 2025. Maxim Group LLC is the sole bookrunner on the deal.
About the Company
The Company is committed to extending human health span and enhancing quality of life in an aging society through its proprietary Reverse Aging Product which is intended to support cellular health and aging-related biological processes at the molecular level, and its artificial intelligence hyper-personalized Organ Regeneration Platform, a proprietary technology developed by our parent company, ROKIT Healthcare, which is intended to provide regenerative medicine solutions in the Americas. Since its founding in 2019, the Company has focused on the research and development of dietary supplements centered around ?-Nicotinamide Mononucleotide. We have launched a range of NMN-based products into global markets, including the United States. Our flagship product line, ROKIT AMERICA NMN, combines NMN with pterostilbene, a naturally occurring antioxidant. Certain of our RAP dietary supplement formulations also include additional ingredients, such as fisetin, which we incorporate based on internal research and development focused on supporting cellular health and aging-related biological processes. These products are regulated as dietary supplements and do not require premarket approval by the US FDA. Our ability to compete depends primarily on brand recognition, product quality, marketing execution, and consumer trust, rather than proprietary exclusivity over individual supplement ingredients.